TransCode Therapeutics Appoints MicroRNA Pioneer, Dr. Frank Slack, to its Advisory BoardGlobeNewsWire • 09/08/22
TransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business UpdateGlobeNewsWire • 08/15/22
TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for OncologyGlobeNewsWire • 08/02/22
TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent PortfolioGlobeNewsWire • 07/11/22
TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of AwardGlobeNewsWire • 06/01/22
TransCode Therapeutics To Participate at H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/20/22
TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business UpdateGlobeNewsWire • 05/16/22
TransCode Therapeutics' CTO, Dr. Zdravka Medarova, to Moderate 7th Annual RNA Medicine SymposiumGlobeNewsWire • 04/13/22
TransCode Therapeutics, Inc. (RNAZ) CEO Michael Dudley on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/07/22
TransCode Therapeutics Interview to Air on Bloomberg U.S. on the RedChip Money Report®GlobeNewsWire • 03/25/22
TransCode Therapeutics Announces Article Published in the Journal Cancers Detailing the Potential for Short RNA-based Drugs in Cancer and a Broad Range of DisordersGlobeNewsWire • 03/23/22
TransCode Therapeutics To Participate at H.C. Wainwright BioConnect ConferenceGlobeNewsWire • 01/06/22
TransCode Therapeutics To Participate at MedInvest Oncology Investor ConferenceGlobeNewsWire • 12/07/21
TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial ResultsBusiness Wire • 11/15/21
TransCode Therapeutics Announces Participation in the Q4 Virtual Investor SummitNewsfile Corp • 11/09/21
TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology OfficerBusiness Wire • 09/30/21
RNAZ Stock Alert: The Breast Cancer Study News Sending TransCode Therapeutics Soaring TodayInvestorPlace • 09/23/21